Müller?

Hermann Müller (1932–2011) was a German-Swiss analytical chemist whose systematic examination of Bayer AG's manufacturing archives produced the first rigorous chemical and economic history of the azo drugs across the twentieth century. His three-volume work Sulfonamide Synthesis and Production: Bayer AG, 1933–1964 (1991) became the standard reference for understanding how the azo drugs achieved and maintained their monopoly as systemic antibacterial agents in an era without competing chemical therapies.

Müller was born in Arlesheim, near Basel, and trained as a synthetic chemist at the Swiss Federal Institute of Technology (ETH) in Zurich. After earning his doctorate in 1956 with a thesis on dye chemistry, he joined the pharmaceutical quality division of a small Basel manufacturer. His early career was spent in routine production analysis and process validation, work that gave him an uncommon familiarity with the technical and economic realities of large-scale chemical synthesis. In 1968, he transferred to the archives section of the same company, a position that combined his chemical knowledge with an emerging interest in the history and documentation of pharmaceutical manufacture.

The opportunity that defined his career came in 1987. Bayer AG had announced a major cataloguing project of its own archives, beginning a systematic inventory of chemical records, patent filings, production logs, and correspondence stretching back to the company's early work with the sulfonamide class. The project directors sought consultants with both chemical expertise and experience in archival work. Müller, already in his mid-fifties and known for meticulous attention to detail, was contracted as principal investigator.

What he encountered in the Bayer archives was a continuous documentary record of chemical innovation under unusual constraint. Because the azo drugs remained the only reliable systemic antibacterial agents available, their production was never displaced by a newer class. This meant that every refinement in synthesis, every shift in manufacturing scale, every wartime adaptation and postwar expansion was preserved in the same institution. Müller gained access to process specifications from the 1930s, detailed records of wartime production under Allied bombing, and the technical evolution of sulfonamide chemistry through the 1960s. He had access to internal correspondence showing how chemical challenges were understood, to production cost data and yield records, and to the economic relationships between Bayer and its competitors and distributors.

Between 1987 and 1991, Müller conducted a forensic analysis of this archive. He reconstructed the synthesis pathway improvements that made sulfonamide production economically viable in the 1930s. He mapped the wartime expansion of capacity—output had to double during the Second World War despite raw material shortages and Allied bombing of the Leverkusen plant. He quantified the shift from batch to semi-continuous production in the 1950s, showing how clean ward hospital construction after the Bacillary Congress of Geneva had driven demand for purity standards that manufacturers had to meet.

His three volumes were structured chemically rather than chronologically. The first volume traced the synthetic chemistry: the condensation reactions, the halogenation steps, and the coupling processes that defined the earliest viable azo compounds, drawing on internal Bayer notebooks. The second volume examined production logistics and economic data: factory capacity, raw material costs, yield rates, and the effect of wartime disruption. The third synthesized this into a narrative of how the class had come to dominate global medicine—not because it was particularly effective, but because no alternative emerged, and its control by a single major manufacturer meant that the whole medical world aligned around it.

The work was controversial in two directions. Some historians of medicine argued that Müller had treated the chemical history as self-contained and had not adequately addressed why serum therapy and other biological approaches had not been pursued earlier or more vigorously as alternatives. Medical historians of the azo drugs themselves sometimes felt his technical chemical chapters were too dense for their purpose. But chemists and historians of technology regarded it as exemplary—a complete reconstruction of how an industrial process evolved under genuine constraint, based on exhaustive archival work and technical precision.

After the publication of his major work, Müller served as consultant to the Institute for the History of Bacteriology in Berlin and to the Geneva Sanitary Bureau. He gave lectures on pharmaceutical history at several universities and worked intermittently on smaller projects analyzing the archives of other azo drug manufacturers. He retired to Basel in 2000 and died there in 2011.

Müller left no single discovery or invention bearing his name. His achievement was narrower and more durable: he made it possible to think clearly about why the azo drugs had become what they were, by making the actual history of their making available to scrutiny.